Contents Menu

Aprepitant relieves chemotherapy-induced inappetance in colorectal cancer patients in the acute phase of mod-erate emetogenic chemotherapy: An observational study based on self-report diaries

The bulletin of the Yamaguchi Medical School Volume 60 Issue 1-2 Page 19-26
published_at 2013
A050060000103.pdf
[fulltext] 437 KB
Title
Aprepitant relieves chemotherapy-induced inappetance in colorectal cancer patients in the acute phase of mod-erate emetogenic chemotherapy: An observational study based on self-report diaries
Creators Kaneko Tadashi
Creators Furuya Takumi
Creators Fujimoto Takuya
Creators Kamimura Yoshio
Creators Takemoto Norikazu
Creators Hayashi Hideto
Creators Yahara Noboru
Creators Inoue Takeshi
Creators Saeki Toshihiro
Creators Hayashi Hiroto
Source Identifiers
Creator Keywords
antiemesis palonosetron food intake water intake
Background: The novel drugs aprepitant (APR) and palonosetron are rec- ommended for the treatment of chemotherapy-induced nausea and vomiting. Here, we assessed the effects of these antiemetics using a self-report diary.Methods: This was a retrospective observational study based on data from 87 pa- tients spectively collected in 222 self-report diaries. We assessed the effect of vomiting and nausea on the patients'quality-of-life, and food and water intake. A“no event”was treated as a favorable outcome. We compared the rates of no event be-tween the first course of chemotherapy and subsequent courses, as well as among the different emetogenic risks and post-chemotherapy phases. We also studied the effect of APR in a subgroup of colorectal cancer patients receiving moderate emetogenic chemotherapy.Results: Nearly 90% of patients reported that the vomiting and nausea did not af- fect their quality-of-life
Languages eng
Resource Type departmental bulletin paper
Publishers Yamaguchi University School of Medicine
Date Issued 2013
File Version Version of Record
Access Rights open access
Relations
[ISSN]0513-1812
[NCID]AA00594272
Schools 医学部附属病院